(NASDAQ:HWKN), ROSEVILLE, Minn., Jan. 29, 2025 (GLOBE NEWSWIRE) — The Board of Directors of Hawkins, Inc. (Nasdaq: HWKN), at its meeting on January 29, 2025, declared a quarterly cash dividend of $0.18 per share, payable February 28, 2025, to shareholders of record at the close of business on February 14, 2025. Hawkins has consistently paid […]

(TSX-V:RBX), Highlights: Following a competitive process previously announced, we have retained Sprott Lending Corp (“Sprott“) has our debt provider Sprott received investment committee approval for up to US$105 million project financing debt facility, with the option to increase it to up to US$130 million Debt margin of 6.5% per annum with an additional interest rate

(NYSE:HIW), RALEIGH, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) — Highwoods Properties, Inc. (NYSE:HIW) announces its Board of Directors has declared a cash dividend of $0.50 per share of common stock for the quarter ended December 31, 2024, which equates to an annualized dividend of $2.00 per share. This quarterly dividend is payable on March 11,

(NASDAQ:SLNO), REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February: Guggenheim SMID Cap Biotech ConferencePresentation Date: Thursday, February 6, 2025 at 2:00 PM

(NASDAQ:ROIV),(NasdaqGM:ROIVW), BASEL, Switzerland and LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 10, 2025, to report its financial results for the third quarter ended December 31, 2024, and provide a business

(NASDAQ:CRGX), CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients. CARGO to implement a workforce reduction of approximately 50%. Phase 1 dose escalation study enrollment for CRG-023 on track to initiate in Q2 2025. SAN CARLOS, Calif., Jan.

(NasdaqGM:CLMB), EATONTOWN, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) — Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb”, the “Company”, “we”, or “our”), a value-added global IT channel company providing unique sales and distribution solutions for innovative technology vendors, today announced the appointment of John McCarthy as the new Chairman of the Board of Directors (the “Board”), effective

(NasdaqGM:ARTV), SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr.

Saving PTK: The Whistleblower's Fight for Truth and Change, by Toni Marek, examines concerns about Phi Theta Kappa (PTK), the nation's largest honor society for community college students, and the challenges that have shaped the past decade. A decade ago, Marek was among the first to publicly raise concerns about PTK's leadership and culture. Since

(NYSE:NVO), NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action on behalf of purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, inclusive (the “Class Period”). A class action lawsuit has